{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:41:33Z","timestamp":1776231693323,"version":"3.50.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Myocardial ischemia\u2013reperfusion (I\/R) injury remains a major determinant of outcome after acute myocardial infarction (AMI) despite timely primary percutaneous coronary intervention (PPCI). Although epicardial patency is routinely restored, incomplete tissue reperfusion, microvascular obstruction (MVO), intramyocardial hemorrhage (IMH), and maladaptive inflammation often limit myocardial salvage and promote adverse remodeling. In this narrative review, I\/R injury is synthesized as a spatiotemporal, multicompartment network in which dominant mechanisms and actionable nodes shift from seconds to weeks and across cardiomyocytes, the coronary microvasculature, and systemic immune\u2013metabolic programs. This framework helps explain why many single-target, single-window cardioprotective strategies have shown robust preclinical benefit yet failed to improve outcomes in contemporary ST-segment elevation myocardial infarction (STEMI) trials, where heterogeneity in ischemic time, comorbidities, microvascular injury patterns, and background pharmacotherapy reshapes injury topology and dilutes target-dominant subgroups. We propose an endpoint-anchored approach that distinguishes cardiomyocyte-vulnerability, microvascular-bottleneck, and resolution-deficient endotypes and matches interventions to phase-specific objectives using compartment-aligned endpoint stacks and target-engagement biomarkers. Within this rationale, defined bioactive compounds derived from traditional Chinese medicine (TCM) and selected standardized preparations are evaluated as potential network modulators with plausible actions on mitochondrial vulnerability, immunothrombosis, endothelial integrity, and inflammatory resolution. Translational priorities include stringent standardization, pharmacokinetic\/pharmacodynamic (PK\/PD)-informed dosing, PCI-compatible safety and drug\u2013drug interaction assessment, and biomarker-guided trial designs enriched for mechanistically matched endotypes.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1797330","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:41:32Z","timestamp":1776228092000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Myocardial ischemia\u2013reperfusion injury after acute myocardial infarction: spatiotemporal mechanisms and endotype-matched multi-target modulation by compounds from traditional Chinese medicine"],"prefix":"10.3389","volume":"13","author":[{"given":"Lin","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Acupuncture, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqian","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Tuina, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyang","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Acupuncture, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 Esc guidelines for the management of acute coronary syndromes","volume":"44","author":"Robert","year":"2023","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41569-020-0403-y","article-title":"Myocardial ischaemia-reperfusion injury and cardioprotection in perspective","volume":"17","author":"Gerd","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jcmg.2024.02.003","article-title":"Microvascular obstruction and intramyocardial hemorrhage in reperfused myocardial infarctions: pathophysiology and clinical insights from imaging","volume":"17","author":"Keyur","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/eurheartj\/ehae058","article-title":"Novel cardioprotective approaches in ischaemic heart disease","volume":"45","author":"Gemma","year":"2024","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/10742484231179613","article-title":"Cardioprotection and its translation: a need for new paradigms? Or for new pragmatism? An opinionated retro- and perspective","volume":"28","author":"Gerd","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.tem.2023.10.010","article-title":"Regulated cell death in myocardial ischemia-reperfusion injury","volume":"35","author":"Qi","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4049\/jimmunol.2200508","article-title":"Panoptosis: a unique innate immune inflammatory cell death modality","volume":"209","author":"Nagakannan","year":"2022","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated tca cycle proteins","volume":"375","author":"Peter","year":"2022","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.897087","article-title":"The endothelial glycocalyx: a possible therapeutic target in cardiovascular disorders","volume":"9","author":"Anastasia","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117476","article-title":"Neutrophil extracellular traps and cardiovascular disease: associations and potential therapeutic approaches","volume":"180","author":"Yiyue","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jacbts.2022.06.008","article-title":"Mechanisms of the \u201cNo-reflow\u201d phenomenon after acute myocardial infarction: potential role of pericytes","volume":"8","author":"Sanjiv","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395786","article-title":"Lactate and lactylation in macrophage metabolic reprogramming: current progress and outstanding issues","volume":"15","author":"Bangjun","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.jacc.2024.02.056","article-title":"Reperfusion injury in patients with acute myocardial infarction: jacc scientific statement","volume":"83","author":"Frederick","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2023.19524","article-title":"Traditional Chinese medicine compound (tongxinluo) and clinical outcomes of patients with acute myocardial infarction: the cts-ami randomized clinical trial","volume":"330","author":"Yuejin","year":"2023","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2024.103039","article-title":"Traditional Chinese medicine injections with activating blood circulation, equivalent effect of anticoagulation or antiplatelet, for acute myocardial infarction: a systematic review and meta-analysis of randomized clinical trials","volume":"82","author":"Xueyan","year":"2024","journal-title":"Complement Ther Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","article-title":"Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies","volume":"43","author":"Stefan","year":"2022","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1093\/eurheartj\/ehad510","article-title":"Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases","volume":"44","author":"Dominik","year":"2023","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.842619","article-title":"Left ventricular strain is associated with myocardial recovery following st-elevation myocardial infarction, a prospective longitudinal cmr study","volume":"9","author":"Mohamad","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jcmg.2023.01.021","article-title":"Impact of persistent microvascular obstruction late after stemi on adverse lv remodeling: a cmr study","volume":"16","author":"Vicente","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.jcin.2023.08.030","article-title":"The Index of microcirculatory resistance after primary pci: a pooled analysis of individual patient data","volume":"16","author":"Mohamed","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1640748","article-title":"Cell-Free mitochondrial DNA as a pro-inflammatory agent in blood circulation: mechanisms, therapeutic implications, and clinical challenges in immune dysregulation","volume":"16","author":"Yangyang","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cells15010033","article-title":"Cell-Free nucleic acids in cardiovascular disease: from biomarkers to mechanistic drivers and therapeutic opportunities","volume":"15","author":"Hannah","year":"2026","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00392-021-01855-6","article-title":"Global longitudinal strain improves risk assessment after st-segment elevation myocardial infarction: a comparative prognostic evaluation of left ventricular functional parameters","volume":"110","author":"Magdalena","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.122.010259","article-title":"Prognostic importance of nt-probnp (N-terminal pro-B-type natriuretic peptide) following high-risk myocardial infarction in the paradise-mi trial","volume":"16","author":"Karola","year":"2023","journal-title":"Circ Heart Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jcmg.2024.03.012","article-title":"Cardiac magnetic resonance evaluation of lv remodeling post-myocardial infarction: prognosis, monitoring and trial endpoints","volume":"17","author":"Mark Colin","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tcm.2022.02.005","article-title":"Myocardial ischemia-reperfusion injury and the influence of inflammation","volume":"33","author":"Michiel","year":"2022","journal-title":"Trends Cardiovasc Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.027600","article-title":"Impact of reperfusion on temporal immune cell dynamics after myocardial infarction","volume":"12","author":"Richard Ying Ke","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-021-00433-y","article-title":"Molecular mechanisms and consequences of mitochondrial permeability transition","volume":"23","author":"Massimo","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1652683","article-title":"Regulation of mitochondrial dynamics in cardiomyocytes: implications for cardiac health and disease","volume":"13","author":"Tengxu","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04906-6","article-title":"Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease","volume":"13","author":"Anqi","year":"2022","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413492","article-title":"Mechanisms and therapeutic potential of multiple forms of cell death in myocardial ischemia-reperfusion injury","volume":"25","author":"Shinya","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1016\/j.csbj.2021.07.038","article-title":"From pyroptosis, apoptosis and necroptosis to panoptosis: a mechanistic compendium of programmed cell death pathways","volume":"19","author":"Yaqiu","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10495-024-01969-y","article-title":"Cuproptosis and copper deficiency in ischemic vascular injury and repair","volume":"29","author":"Jiayi","year":"2024","journal-title":"Apoptosis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1016\/j.cell.2023.05.039","article-title":"Cooperative sensing of mitochondrial DNA by Zbp1 and cgas promotes cardiotoxicity","volume":"186","author":"Yuanjiu","year":"2023","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13920","article-title":"Mitochondria-Derived damage-associated molecular patterns and inflammation in the ischemic-reperfused heart","volume":"237","author":"May-Kristin","year":"2023","journal-title":"Acta Physiol (Oxf)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185934","article-title":"Microvascular obstruction in acute myocardial infarction, a potential therapeutic target","volume":"12","author":"Mina","year":"2023","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Konstantin","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s12265-025-10676-1","article-title":"Characterization of neutrophil extracellular traps in acute myocardial infarction: a translational study","volume":"18","author":"Sergio","year":"2025","journal-title":"J Cardiovasc Transl Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557250","article-title":"Cross-Talk between cardiac lymphatics and immune cells regulates inflammatory response and cardiac recovery after myocardial infarction","volume":"16","author":"Zhihua","year":"2025","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1489438","article-title":"Lactate metabolism and lactylation in cardiovascular disease: novel mechanisms and therapeutic targets","volume":"11","author":"Han","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/eurheartj\/ehad787","article-title":"Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis","volume":"45","author":"Zheng","year":"2023","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/eurheartj\/ehae089","article-title":"Injury minimization after myocardial infarction: focus on extracellular vesicles","volume":"45","author":"Lucio","year":"2024","journal-title":"Eur Heart J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144668","article-title":"Prospects for precision medicine in acute myocardial infarction: patient-level insights into myocardial injury and repair","volume":"12","author":"Mohammad","year":"2023","journal-title":"J Clin Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmccpl.2024.100278","article-title":"Cardioprotective strategies in myocardial ischemia-reperfusion injury: implications for improving clinical translation","volume":"11","author":"Chao","year":"2025","journal-title":"J Mol Cell Cardiol Plus"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-618","article-title":"Preclinical systematic review & meta-analysis of cyclosporine for the treatment of myocardial ischemia-reperfusion injury","volume":"10","author":"Joshua","year":"2022","journal-title":"Ann Transl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10557-020-07074-x","article-title":"Is there a future for remote ischemic conditioning in acute myocardial infarction?","volume":"36","author":"Thomas","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.jacc.2024.08.069","article-title":"Artificial intelligence in cardiovascular clinical trials","volume":"84","author":"Jonathan","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.jacc.2024.03.408","article-title":"Clinical outcomes associated with Various microvascular injury patterns identified by cmr after stemi","volume":"83","author":"Ivan","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01259-7","article-title":"Il-6 and cardiovascular risk: a narrative review","volume":"27","author":"Nehal","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.106995","article-title":"Challenges facing the clinical translation of cardioprotection: 35 years after the discovery of ischemic preconditioning","volume":"144","author":"Claudia","year":"2022","journal-title":"Vascul Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-021-00893-5","article-title":"Improving preclinical assessment of cardioprotective therapies (impact) criteria: guidelines of the eu-cardioprotection cost action","volume":"116","author":"Sandrine","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052103","article-title":"Sodium-Glucose transporter-2 inhibitors (Sglt2i) and myocardial ischemia: another compelling reason to consider these agents regardless of diabetes","volume":"26","author":"Francesco","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14227976","article-title":"No-Reflow during coronary interventions: a narrative review","volume":"14","author":"Sara","year":"2025","journal-title":"J Clin Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.hlc.2022.12.015","article-title":"New drug targets and preclinical modelling recommendations for treating acute myocardial infarction","volume":"32","author":"Yuanzhao","year":"2023","journal-title":"Heart Lung Circ"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1703454","article-title":"Application of network pharmacology in traditional Chinese medicine for the treatment of cardiac diseases","volume":"16","author":"Xi","year":"2025","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040538","article-title":"Trends and pitfalls in the progress of network pharmacology research on natural products","volume":"18","author":"Alexander","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030309","article-title":"Exploring the mechanism of salvianolic acid B against myocardial ischemia-reperfusion injury based on network pharmacology","volume":"17","author":"Qianping","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1165212","article-title":"Effect of tanshinone iia for myocardial ischemia\/reperfusion injury in animal model: preclinical evidence and possible mechanisms","volume":"14","author":"Peng-Chong","year":"2023","journal-title":"Front Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.927611","article-title":"Puerarin: a protective drug against ischemia-reperfusion injury","volume":"13","author":"Minglang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1187910","article-title":"Review on the protective mechanism of astragaloside iv against cardiovascular diseases","volume":"14","author":"Chunkun","year":"2023","journal-title":"Front Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cjtee.2022.06.008","article-title":"Pharmacological properties and mechanisms of notoginsenoside R1 in ischemia-reperfusion injury","volume":"26","author":"Ting","year":"2022","journal-title":"Chin J Traumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/jpp\/rgac015","article-title":"Research progress on the pharmacy of tetramethylpyrazine and its pharmacological activity in cardiovascular and cerebrovascular diseases","volume":"74","author":"Yafang","year":"2022","journal-title":"J Pharm Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1021\/acs.jnatprod.9b00949","article-title":"Scientific and regulatory approach to botanical drug development: a U.S","volume":"83","author":"Charles","year":"2020","journal-title":"Fda Perspective. J Nat Prod"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/eurheartj\/ehad863","article-title":"The \u201810 Commandments\u2019 for the 2023 esc guidelines for the management of acute coronary syndromes","volume":"45","author":"Robert","year":"2024","journal-title":"Eur Heart J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-022-00681-w","article-title":"Traditional Chinese medicine injections: where we are after 80-year development","author":"Wenwen","year":"2022","journal-title":"Chin Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jacc.2025.07.064","article-title":"Targeting inflammation after acute myocardial infarction","volume":"86","author":"Antonino","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599511","article-title":"Damage-Associated molecular patterns in myocardial infarction and heart transplantation: the road to translational success","volume":"11","author":"Max","year":"2020","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jacc.2019.05.024","article-title":"Cardiac mri endpoints in myocardial infarction experimental and clinical trials: jACC scientific expert panel","volume":"74","author":"Borja","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/cvr\/cvaa321","article-title":"Network medicine in cardiovascular research","volume":"117","author":"Laurel","year":"2020","journal-title":"Cardiovasc Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2025.101382","article-title":"Ischemia - reperfusion injury: a roadmap to precision therapies","volume":"104","author":"Wei","year":"2025","journal-title":"Mol Aspects Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2018.09.086","article-title":"Multitarget strategies to reduce myocardial ischemia\/reperfusion injury: jacc review topic of the week","volume":"73","author":"Sean","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1797330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:41:49Z","timestamp":1776228109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1797330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":71,"alternative-id":["10.3389\/fcvm.2026.1797330"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1797330","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1797330"}}